Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 6/20 | 0.43 |
| ▸ | RXRA | P19793 | 5/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.38 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16455475 | 0.93 | NR1H2 (0.43) | NR1H2RXRANR1H3PTGS2HSP90AA1 | |
| SCHEMBL16455495 | 0.93 | NR1H2 (0.44) | NR1H2RXRANR1H3PTGS2HSP90AA1 | |
| SCHEMBL16455482 | 0.88 | HSP90AA1 (0.49) | NR1H2RXRANR1H3PTGS2HSP90AA1 | |
| SCHEMBL16455493 | 0.85 | RXRA (0.49) | NR1H2RXRANR1H3PTGS2HSP90AA1 | |
| SCHEMBL16455494 | 0.84 | NR1H2 (0.46) | NR1H2RXRANR1H3PTGS2HSP90AA1 | |
| SCHEMBL16455526 | 0.82 | NR1H2 (0.55) | NR1H2RXRANR1H3PTGS2HSP90AA1 | |
| SCHEMBL18800493 | 0.82 | HSP90AA1 (0.42) | NR1H2RXRANR1H3HSP90AA1PIK3CA | |
| SCHEMBL15229884 | 0.82 | NR1H2 (0.57) | NR1H2RXRANR1H3PTGS2HSP90AA1 | |
| SCHEMBL16455488 | 0.82 | RXRA (0.51) | NR1H2RXRANR1H3PTGS2HSP90AA1 | |
| SCHEMBL16455668 | 0.81 | NR1H2 (0.48) | NR1H2RXRANR1H3PTGS2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | ALEXAR THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | NR1H2, NR1H3, RXRA | NR1H2 1/4885RXRA 3/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.